New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
16:15 EDTDNDNDendreon names W. Thomas Amick as president, CEO
Dendreon announced that its board has appointed W. Thomas Amick as president and CEO, effective immediately. Amick has also been appointed to the company’s board of directors. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and CEO for personal reasons. Johnson will work with Amick through August 15 to ensure a smooth transition. Most recently from 2010 to 2012, Amick served as chairman and CEO of Discovery Labs, a specialty biotechnology company.
News For DNDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
10:00 EDTDNDNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:30 EDTDNDNDendreon upgraded to Neutral from Sell at Roth Capital
Subscribe for More Information
November 10, 2014
10:14 EDTDNDNHigh option volume stocks
High option volume stocks: UN PAGP PHH RGLS DF URA CERS DNDN LGF CALL
09:35 EDTDNDNActive equity options trading
Subscribe for More Information
09:20 EDTDNDNOn The Fly: Pre-market Movers
Subscribe for More Information
05:52 EDTDNDNDendreon files for Chapter 11 bankruptcy
Dendreon announced that it has reached agreements on the terms of a financial restructuring with certain holders of the company’s 2.875% Convertible Senior Notes due 2016 representing approximately 84% of the $620M aggregate principal amount of the 2016 Notes. Under the terms of the agreements, the financial restructuring may take the form of a stand-alone recapitalization or a sale of the company or its assets. The transactions under the agreements will enable continued delivery of Provenge without disruption or impact to access for providers and appropriate patients in need of this revolutionary personalized immunotherapy treatment, Dendreon said. To implement the financial restructuring, Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on November 10. Dendreon said it has "significant liquidity to support all of its operations during the restructuring process," with approximately $100M of cash, cash equivalents and investments on hand as of November 7, and does "not anticipate the need to raise any incremental financing in connection with the restructuring process." The stock closed Friday up 11c to 94c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use